
|Videos|February 15, 2021
Relapsed/Refractory HER2+ Metastatic Breast Cancer
Recommendations for managing 2 patient cases specific to HER2-positive metastatic breast cancer and optimizing therapy for specific patient populations within the HER2-positive space based on emerging treatments and changes to standards of care.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
EC Approves Encorafenib/Cetuximab/FOLFOX in 1L BRAF V600E–Mutant mCRC
2
Zanzalintinib/Atezolizumab Misses Survival End Point in Non-MSI-H mCRC Subgroup
3
Sigvotatug Vedotin Does Not Significantly Improve Survival in NSCLC Trial
4
The Moonlight Shift: Dr Joshua Richter on Myeloma, Myths, and the C-Word
5
















































































